Press release
Creative Biolabs Updates Antibody Catalog for COVID-19 Research
The SARS-COV-2 is rampaging throughout the world, posing threat to the health of human beings, hindering the economic growth of many countries, meanwhile challenging the current medical technologies. There are 16.3M confirmed cases, 649K death, and 9.41M recovered, updated on July 27, 2020. Highly infections as it is, the SARS-COV-2 transmits from person to person, through droplets produced when the infected person coughs, sneezes, or speaks, which can fall on people nearby (usually within 6 feet). People may also get infected if touching the mouth, nose, and eyes after touching the contaminated objects.As a reliable supplier of engineered antibody products, Creative Biolabs has instantly launched emergency plans to join the fight against COVID-19. With the experience gained when dealing with SARS and MERS epidemics, Creative Biolabs quickly organized over 400 types of therapeutic antibodies that can be applied to the study on COVID-19, which target crucial genes such as NP, S1, S1 RBD, S2 of SARS-CoV-2, SARS-CoV, and MERS-CoV.
Catalog of SARS-CoV-2 antibody products
* 2019-nCoV NP
Rabbit Anti-SARS-CoV-2 (2019-nCoV) NP Recombinant Antibody
Human Anti-SARS-CoV-2 (2019-nCoV) NP Recombinant Antibody
Rabbit Anti-SARS-CoV-2 (2019-nCoV) NP Polyclonal Antibody
* 2019-nCoV S
Mouse Anti-2019-nCoV S1 Recombinant Antibody
Rabbit Anti-SARS-CoV-2 (2019-nCoV) S1 Recombinant Antibody
Human Anti-SARS-CoV-2 (2019-nCoV) S1 Recombinant Antibody
Mouse Anti-SARS-CoV-2 (2019-nCoV) S (RBD) Recombinant Antibody
Mouse Anti-SARS-CoV-2 (2019-nCoV) S (RBD) Polyclonal Antibody
Human Anti-SARS-CoV-2 (2019-nCoV) S2 Recombinant Antibody
Features:
* The majority of those antibody products are applicable for ELISA and WB. Other applications like Neut, Biosensors, Dot, FACS, FC, etc. can also find counterparts.
* All of the above-mentioned antibodies are obtained from mammalian, including camelid, human, mouse, rodent
Empowered by the sophisticated hybridoma development and phage display systems, Creative Biolabs can develop the recombinant antibodies efficiently and cost-effectively, which are also guaranteed with high purity, high specificity, and low or no immunogenicity. Since the outbreak of COVID-19, Creative Biolabs has received a large number of orders requesting the antibodies.
To better alleviate badly needs on detection kits, Creative Biolabs is providing 3 types of kits for SARS-COV-2 detection, which can effectively make up for the deficiencies of nucleic acid tests, to generate instant testing results.
Detection Kits Based on Fluorescent RT-PCR Method
Detection Kits Based on Colloidal Gold Method
Detection Kits Based on ELISA
The good news is that several vaccines have made huge breakthroughs in their clinical tests, with hundreds of candidates still on the way. As for the institutes and pharmaceutical companies that are dedicated to developing new drugs and vaccines against COVID-19, Creative Biolabs is always willing to offer first-level products and solutions. More details can be accessed at https://www.creativebiolabs.net/.
Creative Biolabs
45-1 Ramsey Road, Shirley, NY 11967, USA
1-631-619-7922
marketing@creative-biolabs.com
About the Company
Creative Biolabs is a reliable supplier of recombinant antibody (rAb) products, providing antibody/peptide libraries, Biosimilar cell lines, Chimeric antigen receptor (CAR) products, antibody-drug conjugates (ADCs) to engineered antibodies such as therapeutic antibodies, single-domain antibodies, bispecific antibodies and intrabodies.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Creative Biolabs Updates Antibody Catalog for COVID-19 Research here
News-ID: 2101425 • Views: …
More Releases from Creative Biolabs
Creative Biolabs-Improving Antibody Engineering Through Recombinant Approaches
Abstract: Creative Biolabs is a preeminent contract research organization (CRO) at the vanguard of recombinant antibody technologies, catering to the varied demands of scientists worldwide with high-quality human, humanized, and chimeric antibodies.
To succeed or fail in the cutthroat field of antibody research, one must carefully consider the pros and cons of using human, humanized, or chimeric antibodies, and for researchers and pharmaceutical developers, it is crucial to understand the intricacies…
Exosome Display Technology for Antibody Generation, Targeted Delivery, and Prote …
Scientists now have realized that exosomes, representing a novel mode of intercellular communication, contribute to a wide range of biological processes in health and disease including cancer. Especially, growing evidence shows that tumor-derived exosomes play critical roles in cancer. Exosomes and their cargos may serve as cancer prognostic markers, therapeutic targets or even as anticancer drug‐carrier.
Exosome display is an innovative methodology enabling the manipulation of exosome protein content by the…
Exosomes News: Creative Biolabs Introduces Exosome Purification Services for Car …
As exosomes can transmit the information of donor cells to recipient cells through the proteins, mRNA, miRNA carried by them, thus to realize the information and material exchange between cells, they have been a hot topic recently as being used as a drug carrier to transport drugs.
"Future research may focus on how to improve the cargo loading of exosomes," said the senior scientist from Creative Biolabs, “at present, some…
Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Researc …
As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and kill tumor cells. Up to now, two OV drugs have been…
More Releases for SARS
Existing Drugs May Inhibit SARS-CoV-2 Virus
The COVID-19 pandemic has caused more than 600,000 deaths in the United States since the start of 2020 and more than 4 million globally. The search for effective treatments against the disease are ongoing, and one hurdle is that SARS-CoV-2, the virus that causes COVID-19, has a number of tricks up its molecular sleeve when it comes to infecting people.
In a recent study published in Nature Communications Biology, researchers from…
Global Severe Acute Respiratory Syndrome(SARS) Therapeutics Sales Market Report …
In this report, the global Severe Acute Respiratory Syndrome(SARS) Therapeutics market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.
Geographically, this report split global into several key Regions, with sales (K Pcs), revenue (Million USD), market share and growth rate of Severe Acute Respiratory Syndrome(SARS) Therapeutics for these…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017 to its growing collection of premium market research reports.
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 Pharmaceutical Re …
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H2 2017”. Severe acute respiratory syndrome (SARS) is a serious, potentially life-threatening viral infection caused by virus from the Coronaviridae family.
Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305521
Symptoms include cough, chills and shaking, headache, muscle aches, diarrhea, dizziness, nausea and vomiting. Risk factors include gene variation in the…
Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Insigh …
Market Research Hub, “Severe Acute Respiratory Syndrome Coronavirus Infection Pipeline Insights”, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection by development stage, therapy type, route of administration…
Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017 to its growing collection of premium market research reports.
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Severe Acute Respiratory Syndrome (SARS) - Pipeline Review, H1 2017, provides an overview of the Severe Acute Respiratory Syndrome (SARS) (Infectious Disease) pipeline landscape.
Severe acute respiratory syndrome (SARS) is a serious, potentially…
